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Background: Metformin (MET) therapy exerts positive effects improving glucose tolerance and preventing the
evolution toward diabetes in insulin resistant patients. It has been shown that adding MET to exercise training does
not improve insulin sensitivity. The aim of this study was to determine the effect of MET and exercise training alone
or in combination on maximal aerobic capacity and, as a secondary end-point on quality of life indexes in
individuals with insulin resistance.
Methods: 75 insulin resistant patients were enrolled and subsequently assigned to MET (M), MET with exercise
training (MEx), and exercise training alone (Ex). 12-weeks of supervised exercise-training program was carried out in
both Ex and MEx groups. Cardiopulmonary exercise test and SF-36 to evaluate Health-Related Quality of Life
(HRQoL) was performed at basal and after 12-weeks of treatment.
Results: Cardiopulmonary exercise test showed a significant increase of peak VO2 in Ex and MEx whereas M
showed no improvement of peak VO2 (Δ VO2 [CI 95%] Ex +0.26 [0.47 to 0.05] l/min; Δ VO2 MEx +0.19 [0.33 to 0.05]
l/min; Δ VO2 M −0.09 [−0.03 to -0.15] l/min; M vs E p < 0.01; M vs MEx p < 0.01; MEx vs Ex p = ns). SF-36 highlighted
a significant increase in general QoL index in the MEx (58.3 ± 19 vs 77.3 ± 16; p < 0.01) and Ex (62.1 ± 17 vs 73.7 ± 12;
p < 0.005) groups.
Conclusions: We evidenced that cardiopulmonary negative effects showed by MET therapy may be counterbalanced
with the combination of exercise training. Given that exercise training associated with MET produced similar effects to
exercise training alone in terms of maximal aerobic capacity and HRQoL, programmed exercise training remains the
first choice therapy in insulin resistant patients.
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Insulin resistance (IR), a condition in which normal
levels of this hormone produce a sub-optimal biological
response, is considered a primary etiologic factor in the
development of type 2 diabetes (T2DM), ischemic heart
disease but also non-ischemic heart failure [1]. As a
matter of fact IR is associated with a form of cardiomyop-
athy in which the myocardium is incapable of responding* Correspondence: cadedduc@unica.it
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unless otherwise stated.to injuries by altering substrate metabolism to increase en-
ergy efficiency. Moreover, recent studies have shown that
IR plays an important role in determining a reduction
in cardiopulmonary (CP) performance, intended as peak
oxygen uptake, anaerobic threshold, workload and specific
pulmonary function parameters as VE/VCO2 [2]. Lately,
IR has been able to predict the subsequent development
of heart failure, regardless of all the known risk factors, in-
cluding T2DM [3,4].
The U.S. Diabetes Prevention Program (DPP) demon-
strated that lifestyle modification (i.e., low-fat diet andal Ltd. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly credited. The Creative Commons Public Domain
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medication Metformin (MET) reduced the rate of tran-
sition from pre-diabetes to T2DM [5]. The American
Diabetes Association strongly recommends exercise as a
cornerstone therapy for diabetes prevention and, re-
cently, suggested that some individuals with pre-diabetes
be considered for MET treatment [6,7]. However, MET
has also been shown to slightly but significantly reduce
oxygen consumption in a population of healthy individ-
uals [8]. Also, MET reduces average oxygen consump-
tion to a modest but significant extent in IR subjects.
Indeed, this effect is not manifested by all subjects, being
present only in patients featuring a lower degree of IR,
while in patients with very high IR, CP performance is sig-
nificantly improved [9,10]. In an heart failure setting,
Wong et al. showed how metformin did not increase peak
VO2 but reduced the sub-maximal measure of VE/VCO2
slope in patients affected by heart failure and IR [11].
Malin et all showed how exercise training and MET
are both able to improve insulin sensitivity after 12 weeks
of therapy in men and women with pre-diabetes. But
subtle differences among condition means suggest that
by adding MET the full effect of exercise training is
blunted [12].
Moreover previous studies have shown that T2DM
and impaired glucose tolerance (IGT) was significantly
related with low health-related quality of life (HRQoL)
[13]. In addition, more recently studies on individuals
with pre-diabetes showed that patients who were more
physically active had better physical and mental HRQoL
than patients who were inactive. Furthermore the life-
style modification characterized by intentional weight
loss and increased physical activity has an association
with better HRQoL in overweight or obese participants
at high risk for T2DM [14,15].
There is considerable need to better understand the
potential for additive effects of physical activity when
MET is used concurrently in terms of CP performance
and HRQoL. The purpose of this study was to compare
the effect, of exercise training and MET alone or in com-
bination, on maximal aerobic capacity and, as a second-
ary end-point on quality of life indexes in IR patients.
Methods
Study population
Seventy five patients (35 males and 40 females; 46 ±
11 years), consecutively selected from a population of in-
dividuals screened at the Diabetic Centre at our Univer-
sity Hospital, were enrolled on the study from Jan 2009
till Dec 2010. All enrolled patients were white Caucasian
and lived in the geographic area of south Sardinia. All
patients presented impaired glucose tolerance (IGT)
which had been recently identified, and/or impaired fast-
ing glucose (IFG), and all were affected by IR, calculatedin accordance with the homeostatic model assessment
(HOMA) index and defined according to the values of
Bonora et al. [16,17].
Inclusion criteria for both IR patients were: age 20–55
years, echocardiographic left ventricle ejection fraction
(LVEF) ≥55% and absence of echocardiographic wall mo-
tion abnormalities, normal hepatic and renal function
(bilirubin ≤1.5 mg/dl, creatinine ≤2.0 mg/dl). Exclusion
criteria were diabetes, smoking, hypertension with left
ventricle hypertrophy, moderate to severe heart valve
disease, atrial fibrillation or severe arrhythmias. The
presence of dyslipidemia or hypertension without left
ventricle hypertrophy was admitted. The present study
was approved by the Ethical Committee of our Univer-
sity Hospital of the AOU of Cagliari and informed writ-
ten consent was obtained from all participants.
Study protocol
The study was spontaneous, not sponsored and blinded to
investigators. At enrolment, all subjects underwent phys-
ical examination, 12-lead electrocardiogram, M-mode, 2D
and Doppler-echocardiography, CP exercise test (CPET)
and complete blood chemistry. All patients were sub-
sequently assigned to the 3 treatment groups: Group M
(n 25) assigned to 12 weeks of MET therapy, Group Ex
(n 25) assigned to 12 weeks of supervised exercise therapy,
Group MEx (n 25) assigned to 12 weeks of MET therapy
plus supervised exercise (Figure 1). The subjects of the
groups MET and MEx started treatment with 500 mg/day
of metformin. The dose was increased 500 mg/day after
the first week to the clinical dose of 1,000 mg/day. Subjects
remained at this dose for the last 11 weeks remaining. All
the enrolled patients were re-evaluated after 12 weeks.
Primary endpoint of the study was prospectively de-
fined as a significant increase of Vo2 max and secondary
endpoint was the improvement of HRQoL.
Conventional echocardiography
Echocardiographic images were recorded using a commer-
cially available system (Toshiba Artida; Toshiba Corp.,
Tochigi, Japan). LVEF was obtained from the apical 4- and
2-chamber views according to Simpson’s rule and was
considered abnormal when <55%. Pulsed wave Doppler
(PWD) examination was performed of the left ventricle in-
flow from the 4-chamber view with the sample volume
placed between the mitral leaflet tips and the early (E) and
late (A) diastolic peak velocities; E deceleration time
(DecT) was measured and the E/A ratio was derived.
Cardiopulmonary exercise test
All subjects underwent an integrated maximal CP exercise
test on an electrically braked stationary cycle ergometer.
Patients wore a tightly fitting facemask connected to a
capnograph and a sample tube enabling online ventilation
Figure 1 Flow chart on the study design.
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of the tachometer and of oxygen sensors and carbon
dioxide were carried out before each test. Heart rate
and rhythm were continuously monitored using a 12-lead
ECG, recorded every 30 seconds during exercise and a 10-
minute post-exercise recovery period. Arterial blood pres-
sure was ascertained using the standard cuff technique
with a mercury sphygmomanometer placed on the left
arm. Measurements were obtained every 3 minutes during
exercise and at the 1st, 5th, and 10th minute of recovery.
At baseline, patients breathed slowly for a minimum of
5 minutes to stabilize resting gas measurements. A ramp
protocol with an exercise regimen of a 3-min warm-up at
10 W at a pedal speed of 60–65 revolutions/min was ap-
plied, followed by a linear increase in the workload at a
rate of 1 W every 6 s (10 W/min). In this way, at least
10 minutes exercise for each patient was obtained. Pa-
tients were strongly encouraged to continue as long as
possible and reach muscular exhaustion. Breath-by-breath
VO2, carbon dioxide production (V CO2), and minute
ventilation (VE) were measured throughout the test using
Vmax C software (Sensormedics, Yorba Linda, CA). The
end point of the CPET test was determined as per theguidelines for diagnostic evaluation of patients with
chronic ischemic heart disease. Peak VO2 and the con-
sumption of oxygen at anaerobic threshold were expressed
as an absolute value, standardized for weight and in per-
centage compared to the above-mentioned values accord-
ing to the Wasserman formula [18]. Anaerobic threshold
was calculated by two independent skilled operators using
the V-Slope method and compared with values obtained
by graphs VE/VO2 – VE/VCO2 (relationship between
ventilation and oxygen consumption and between ven-
tilation and production of carbon dioxide) and PetO2 -
PetCO2 (concentration of O2 and CO2 at the end of
exhalation). At the peak of exercise the pulse of oxygen
(consumption between oxygen standardized for the heart
rate) and breathing quotient (relationship between CO2 e
O2) were calculated. Subsequently, curve slopes VO2/
Work and VE/VCO2, the latter excluding the final non-
linear portion of the curve, were elaborated.
Health related quality of life assessment
HRQoL was assessed using the Medical Outcome Study
36-item short form health survey (SF-36) questionnaire
[19]. The Italian-language version of the SF-36 is a
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into eight dimensions of health using multi-item scales:
Physical functioning, role limitations due to physical
functioning (Role-physical), Bodily pain, Mental health,
role limitations due to emotional functioning (Role-
emotional), Social functioning, Vitality, and General
Health perceptions. The eight scales were scored from 0
to 100 (worst to best possible health status). For each
dimension, the score represents the mean of item values
obtained by the subject when all the items were com-
pleted or when the number of missing values was no
more than half of the total items. As described else-
where Physical (PCS) and Mental (MCS) Component
Summary assessing the impact of health on physical
and social/emotional function, respectively [19,20].
Exercise training program
The same exercise-training program was carried out in
both exercise groups (Ex and MEx). The training protocol
consisted of a heating phase, a central and a cool-down
phase with stretching exercises. The heating phase (10 mi-
nute) consisted of light stretching, walking and mobility of
trunk, limbs and arms. The central phase consisted in 30
to 50 minutes of cycle ergometer training. Each session
was conducted at a specific intensity target, with a heart
rate range from 60% to 80% of the heart rate reserve
(HRR) based on the subject’s age. Finally, a cool-down
period, consisting of 10 minutes of mobility exercises,
muscular relaxation and stretching was performed.
Six weeks after starting the training program, each
subject underwent a graded exercise test to readjust the
training workload [21].
Statistical analysis
A sample size of 17 subjects per arm has been calculated
sufficient, based on our previous studies on the effects of
metformin on VO2 max using CPET [9]. For anthropo-
metric and clinical characteristics of the two groups, con-
tinuous variables were compared with Analysis of Variance
(ANOVA), and categorical variables were compared with
Fisher’s exact test. Differences in echocardiographic pa-
rameters were also evaluated using ANOVA. A two-tailed
value of p < 0.05 was considered statistically significant.
For the multiple statistical test the Bonferroni correction
had been applied. A “per protocol” analysis was performed.
Results
The global population enrolled on the study showed an
average HOMA of 5.48 ± 3.8 and among them mainly
overweight or frankly obese (Table 1). CPET showed in
all the enrolled patients a reduced average peak VO2
(61.8% ± 12%) compared with the theoretical values of a
normal population paired for age and anthropometric
characteristics (Table 1).No differences in term of insulin sensitivity, cardiovas-
cular risk factors and medications taken have been evi-
denced between groups (Tables 2, 3).
Of the initial 75 patients, 5 from the Ex group and 4
from the MEx group were excluded from the study as
they were unable to regularly follow the physical training
program (training attendance <70%).
Variations of the main parameters examined after
12 weeks of therapy in the 3 groups are reported in
Table 3. After 12 weeks of treatment body mass index
(BMI) was significantly lower in the MEx group (CI 95%
29.8 [27.2 to 30.4] vs 31.8 [30.2 to 33.4]; p < 0.05) and in
the M group (CI 95% 28.4 [26.6 to 30.2] vs 29.7 [27.8 to
31.6]; p < 0.05) whereas an insignificant increase in BMI
was observed in the Ex group (CI 95% 28.9 [26.5 to 31.3]
vs 28.3 [26.2 to 30.4]; p = ns). Furthermore, a significant
reduction in HOMA-IR was observed in all 3 groups
(Table 3) with no significant difference in the amount of
reduction between groups (Table 4).
The variations of principal metabolic, anthropometric
and CPET values before and after the 3 treatments and
the differences between groups are reported in Table 4.
Ex group showed improvement in the primary endpoint
(peak oxygen consumption) compared with M group,
whereas MEx group does not improve O2 consumption
with respect to Ex group. The same behavior has been
observed for the Work. Moreover only Ex group showed
an improvement in the Aerobic Threshold with respect
to M and MEx groups (Table 4).
Evaluation of traditional echocardiographic parameters
did not highlight statistically significant differences between
the groups before or after the 3 therapies (data not shown).
CPET highlighted a slight but significant reduction of
peak VO2 (1.45 ± 0.34 l/min vs 1.54 ± 0.40 l/min; p < 0.01)
in the M group while a significant improvement was seen
in the MEx group (1.84 ± 0.38 1/min vs 1.65 ± 0.45 vs p <
0.01) and in the Ex group (1.70 ± 0.51 vs 1.44 ± 0.12 p <
0.05). These trends were also seen when peak VO2 values
were considered with respect to predicted values.
At the same time, an insignificant reduction in work
was highlighted in the M group, in contrast with a signifi-
cant increase of the same parameter in the MEx group
and in the Ex group (Table 3). The anaerobic threshold
was significantly increased in both the MEx group and the
Ex group (Table 3).
With respect to the secondary endpoint, after 12 weeks
of therapy MEx group showed a significant improvement
in physical (56.84 ± 19 vs 76.11 ± 14; p 0.004) mental
(58.75 ± 18 vs 73.68 ± 17; p 0.01) and general (58.33 ± 19 vs
77.29 ± 16; p 0.005) (Figure 2, panel A) health indexes was
observed. Analogously, a significant improvement in phys-
ical (61.9 ± 13 vs 73.56 ± 10; p 0.004) mental (55.8 ± 20 vs
68.33 ± 18; p 0.001) and general (62.14 ± 17 vs 73.70 ± 12;
p 0.003) health indexes was also witnessed in Ex group
Table 1 Clinical features of study population
Age 46.2 ± 11 Glycaemia (mg/dl) 112 ± 14 CPET parameters
Height (cm S) 167.2 ± 9 Insulinaemia(μU/m) 23.7 ± 14.1 VO2 peak (ml/kg/min) 20.16 ± 3.72
Weight (Kg S) 83.3 ± 11 HOMA 5.48 ± 3.8 % 61.83 ± 12
BMI (Kg/m2) 29.8 ± 4.1 Glycemic profile VO2 (l/min) 1.70 ± 0.41
Total cholesterol (mg/dl) 206 ± 14 NG (%) 17% % 73.6 ± 12.3
HDL (mg/dl) 52 ± 10 IFG (%) 71% WORK (Watt) 114.6 ± 31
LDL (mg/dl) 131 ± 24 IGT (%) 28% AT (l/min) 1.01 ± 0.25
Triglycerides (mg/dl) 146 ± 55 IGT + IFG (%) 22% AT% VO2 peak 48.1 ± 11
Hypertension (%) 34.7% Diabetes (%) 0% VO2/WORK 9.7 ± 1.36
Abbreviations: BMI Body Mass Index, HOMA Homeostasis Model Assessment, VO2peak Maximum oxygen uptake, % VO2peak Maximum oxygen uptake in
percentage compared to normal values, Work Maximum work, AT Anaerobic threshold, % AT Anaerobic threshold in percentage compared to VO2peak,
VO2/Work Oxygen uptake-Work rate relationship.
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(56.44 ± 19 vs 56.73 ± 18; p NS) mental (58.35 ± 19 vs
58.46 ± 18; p NS) and general (58.03 ± 19 vs 58.36 ± 18;
p NS) health indexes were observed in M group (Figure 2,
panel C).
No significant differences emerged between variations in
physical, mental and general well-being indexes observed
in the MEx group (PI: 19.26 ± 14 vs 11.66 ± 11; p =NS –
MI: 14.93 ± 14 vs 12.53 ± 10; p = NS – GI: 18.95 ± 15 vs
10.74 ± 12; p = NS), when compared to those seen in
Ex group.
Discussion
Our study found that the IR patients show a reduced
CP performance compared with the normal population.
Most importantly with respect to the primary endpoint
physical exercise treatment alone produce an improve-
ment in oxygen consumption compared with MET ther-
apy alone, whereas MET in association with physical
activity does not improve O2 consumption in compari-
son to therapy with physical exercise alone. Moreover
only physical exercise treatment alone produce an im-
provement in the Aerobic Threshold with respect toTable 2 Risk factors and treatment in the 3 groups
Metformin Exercise
Smoke 4 16% 5
Hypertension 9 36% 12
Hyperchol. 7 28% 8
CAD 0 0% 0
PAD 0 0% 0
Thera
BB 0 0% 0
ACEi 5 20% 7
ARB 3 12% 2
CCB 1 4% 3
Abbreviations: Hyperchol Hypercholesterolemia, CAD coronary artery disease, PAD pe
antagonists, CCB calcium channel blockers.MET therapy alone and MET in association with phys-
ical activity.
The data referring to the secondary endpoint evidenced
that physical exercise, alone or in combination with MET,
is superior to MET treatment alone in improving all indi-
ces of HRQoL, whether physical or mental. We found no
differences on the indices of HRQoL between physical ex-
ercise alone and in combination with MET.
In addition, our study confirmed that the treatment
with MET decreases the peak VO2 and the ability to
work, as already demonstrated by our group in a previ-
ous study [9]. Exercise not only improved the CP per-
formance when used alone, but it was able to cancel the
negative effect of MET, when used in combination with
the drug.
Peak VO2, the maximum capacity of the body to use
oxygen, identifies the highest potential for an individual
to perform aerobic work. This parameter is influenced
by age, sex and level of training, as well as by the pres-
ence of disease or drugs capable of affecting any one of
its components.
The use of exercise capacity as a powerful prognostic
factor in normal subjects is widely acknowledged. AfterTraining Metformin and Exercise Training
20% 5 20%
48% 8 32%
32% 6 24%
0% 0 0%
0% 0 0%
py
0% 0 0%
28% 3 12%
8% 4 16%
12% 1 4%
ripheral arterial disease, BB beta blockers, ACEi ACE inhibitors, ARB angiotensin
Table 3 Metabolic features before and after 12 weeks of therapy
Metformin Exercise Training Metformin and Exercise Training
PRE POST P value PRE POST P value PRE POST P value
Homa 5.1 ± 3.0 3.1 ± 1.3 <0.05 5.5 ± 3.3 3.2 ± 1.1 <0.05 5.6 ± 2.1 3.3 ± 1.2 <0.05
BMI (Kg/m2) 29.7 ± 4.8 28.4 ± 4.6 <0.05 28.3 ± 4.7 28.9 ± 5.6 ns 31.8 ± 3.8 29.8 ± 3.8 <0.01
VO2 (l/min) 1.5 ± 0.4 1.5 ± 0.3 <0.01 1.4 ± 0.1 1.70 ± 0.5 <0.05 1.7 ± 0.5 1.8 ± 0.4 <0.05
% 70.7 ± 9.9 66.7 ± 8.6 <0.01 67.5 ± 6 82.0 ± 17.9 <0.05 76.3 ± 18.1 84.4 ± 16.8 <0.05
WORK (Watt) 108 ± 32 104 ± 30 Ns 104 ± 18 114 ± 8 <0.05 115 ± 27 137 ± 33 <0.01
AT (l/min) 1.0 ± 0.3 1.0 ± 0.2 Ns 0.9 ± 0.1 1.1 ± 0.1 <0.05 1.09 ± 0.3 1.05 ± 0.15 <0.05
VE/VCO2 28.2 ± 2.4 27.8 ± 3.3 Ns 22.4 ± 3.2 23.7 ± 1.9 Ns 23.2 ± 2.3 22.2 ± 1.6 <0.05
VO2/WORK 9.5 ± 1.3 9.2 ± 0.8 Ns 9.7 ± 0.9 9.43 ± 3.3 Ns 9.3 ± 1.3 9.3 ± 0.8 Ns
Abbreviations: HOMA Homeostasis Model Assessment, BMI Body Mass Index, VO2peak Maximum oxygen uptake, % VO2 Maximum oxygen uptake in percentage
compared to normal values, Work Maximum work, AT Anaerobic threshold, VE max Ventilation at maximum exercise, VCO2 carbon dioxide production,
VO2/Work Oxygen uptake-Work rate relationship, VE/VCO2 Ventilatory equivalent for carbon dioxide.
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metabolic equivalents was the strongest predictor of the
risk of death in healthy populations [22]: each metabolic
equivalents increase in exercise capacity conferred a 12
percent improvement in survival. A reduced peak VO2
at baseline in the subjects investigated in the present
study may be interpreted as a depressive effect induced
by IR per se on the CP function, as evidenced in our pre-
vious experience [9]. In agreement with this hypothesis,
a recent community-based study showed that IR predicts
the incidence of heart failure, independently of the
known risk factors, including diabetes [23].
Several animal models have shown a myocardial meta-
bolic incompetence which could lead to an IR cardiomy-
opathy [23]. In fact, IR determines in myocytes an energy
inefficiency as a result of an increased use of fatty acids,
energetically less efficient when compared to glucose. Fur-
thermore, myocytes are unable to utilize glucose in situa-
tions of stress, as occurs in healthy subjects. These
mechanisms, together with the endothelial dysfunction
seen in IR subjects [24], can contribute to myocardial dys-
function [25,26] and the reduction of CP performance that
we observed.
In the Diabetes Prevention Program, MET showed the
ability to slow the progression from a state of impairedTable 4 Differences between metabolic and anthropometric f
M MEx
Homa −1.98 [−2.87 to −1.08] −2.21 [−3.34 to −1.08]
BMI (Kg/m2) −1.35 [−2.27 to −0.43] −1.99 [−2.24 to −1.74]
VO2 (l/min) −0.09 [−0.15 to −0.03] 0.19 [0.05 to 0.33]
% −4.70 [−7.31 to −2.1] 8.11 [1.37 to 14.85]
WORK(Watt) −3.72 [−9.85 to −2.41] 21.85 [12.52 to 31.17]
AT (l/min) −0.06 [−0.14 to 0.02] −0.04 [−0.13 to 0.05]
Abbreviations: HOMA Homeostasis Model Assessment, BMI Body Mass Index, VO2 M
compared to normal values, Work Maximum work, AT Anaerobic threshold.glucose tolerance to T2DM [27,28]. However, several ad-
verse events were attributed to the drug. MET was recog-
nized responsible for a reduction in oxygen consumption in
healthy individuals without IR in comparison with controls
treated with placebo [8]. In vitro studies found that MET
exerts its anti-diabetic effects through inhibition of complex
1 of the mitochondrial respiratory chain (electron transfer
from NADH to coenzyme Q 10) [29,30]. This inhibition
can slow down the transfer of reducing equivalents during
the Krebs cycle and limit the ability of oxidative metabol-
ism. In large muscle groups, the mitochondrial reserve may
be used to some extent during exercise. However, if an in-
hibition of complex 1 reduces this reserve, a critical de-
crease in CP performance can result. Our previous data
showed that MET reduces the average consumption of oxy-
gen for a small but significant extent in IR subjects [9]. It is
of particular interest to note that this depressive effect does
not manifest itself in all subjects, being present only in indi-
viduals with lower degree of IR, while the CP performance
is improved in patients with high and very high IR.
Results from the DPP [5] and other similar studies dem-
onstrated that changes in lifestyle, such as a proper diet
and increased physical activity, play a crucial role in pre-
venting or slowing the progression from a state of IR to a
frank diabetes [31,32]. In the presence of this evidence, aeatures after and before 12 weeks of therapy
P value
EX M vs MEx M vs EX MEx vs EX
2.31 [1.60 to 3.02] ns ns ns
0.67 [−0.01 to 1.35] ns < 0.01 < 0.01
0.26 [0.05 to 0.47] < 0.01 < 0,01 ns
14.42 [9.31 to 19.53] < 0.01 < 0.01 ns
10.22 [1.45 to 18.99] < 0.01 < 0.01 ns
0.18 [0.15 to 0.22] ns < 0.01 < 0.01
aximum oxygen uptake, % VO2peak Maximum oxygen uptake in percentage
Figure 2 Effects of exercise associated with metformin (panel A), of supervised exercise training alone (panel B) and of Metformin therapy
alone (panel C) on physical health index (IF), mental health index (IM) and general health index (GI) after 12 weeks of treatment.
Cadeddu et al. Cardiovascular Diabetology 2014, 13:93 Page 7 of 9
http://www.cardiab.com/content/13/1/93combination of lifestyle changes and MET therapy has
been suggested as the best strategy to control IR and pre-
vent diabetes. The data currently available suggest a bene-
fit of the association in terms of weight loss [33], but alittle if any effect in reducing IR [34], These findings, al-
though preliminary, demonstrate how the clinical effects
of a combination of exercise and MET are complex and
difficult to determine in advance. They confirm the
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be predicted from their individual effects and should be
considered systematically to provide information usable in
the field of public health. Malin et al. indeed demonstrated
that exercise and MET are both able to improve insulin
sensitivity after 12 weeks of therapy, in men and women
with pre-diabetes. But the addition of MET to physical
training did not improve IR and, rather, could have ob-
scured the full benefit of exercise [12].
In the present study, both the exercise associated with
MET and MET alone led to a significant weight loss,
while the exercise used alone did not have this effect.
These data agree with those previously published in the
literature, according to which MET is able to determine
by itself a weight loss. Our findings demonstrate, to our
knowledge for the first time, that treatment with MET
in combination with physical exercise is not superior to
exercise alone, in terms of improving CP performance.
Conversely, the addition of a tailored and supervised
training program in subjects with IR is crucial to reverse
the adverse effects of MET on the oxygen consumption
and allow a greater adherence to therapy.
Various and mostly little-known mechanisms underlie
the MET/exercise interaction and make the effects of
this therapeutic association unpredictable. Both exercise
and MET act on protein kinase activated by the AMP
(AMPK) expression [35] and on the transduction path-
way of the AMPK–eNOS signal. Metformin, an AMPK
activator which can act as an exercise mimetic [36], had
been shown to improve exercise in women with angina
[37] and to improve the endothelial flow reserve [38].
In our study, as previously observed in the study of
Malin et all [12], BMI was significantly lower in the MEx
group and in the M group and not in the Ex group. This
result may be related to a different effect of metformin
and exercise on fat mass and lean body mass distribution.
The last, but not less important remark concerns the
net effect of these therapies on HRQoL related to physical,
mental and general well-being. The data obtained allow us
to confirm the benefit of exercise, without further advan-
tages obtained by its combination with MET. It is our be-
lief that this latest finding is extremely important in a
population of relatively young subjects, which, although at
high risk of developing diabetes and cardiovascular dis-
ease, must however be considered healthy. When MET
is employed, it should always be associated with physical
exercise to counteract the negative effects of drug therapy
on CP performance, contribute to improving the HRQoL
and increase patient compliance, which, as is known, is a
crucial component in their clinical management.
Limitations
The main limitations of the study are related to the study
design. A single blinded design was chosen due to thedifficulties of concealing the exercise. Moreover since the
primary endpoint of our study was to verify the effect of ex-
ercise alone or in combination to metformin on the max-
imal aerobic capacity in comparison with the patients not
performing exercise a “per protocol analysis” was chosen as
more appropriate. Although removing the patients who
were unable to regularly follow the physical training pro-
gram from the final analysis introduces potential bias.
Conclusions
The objective of this study was to evaluate the combined
effect of MET and supervised physical exercise on CP
performance and the HRQoL in subjects with IR. The
negative CP effects induced by MET alone may be com-
pensated by the association with supervised physical ac-
tivity. Exercise training alone, when personalized and
supervised, produces effects similar to the combination
of MET and exercise in terms of CP performance and
HRQoL. Given the lacking evidence of a benefit from
previous studies of the association of MET and exercise
in the control of IR, we confirm that a programmed and
tailored training should be the first choice treatment IR
patients. Further studies are warranted to demonstrate
the real long-term clinical benefit of MET and super-
vised physical exercise alone or associated.
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